Parkinsonism-like delayed neurotoxicity after idecabtagene vicleucel therapy for multiple myeloma: clinicopathological, cerebrospinal fluid, and autopsy analyses

Hiroki Yoshino; Tatsuya Imi; Yuki Nukii; Kohei Hosokawa; Shinya Yamada; Shunichiro Nakagawa; Daiki Higashi; Satoomi Sakai; Shun Fujii; Anna Hiratsuka; Tatsuya Hatada; Takeshi Yoroidaka; Hiroki Mizumaki; Yoshitaka Zaimoku; Akiyo Yoshida; Hiroyuki Maruyama; Satoshi Watanabe; Tomoaki Ueda; Yukinobu Ito; Masafumi Horie; Masanori Toho; Kosei Matsue; Hiroyuki Takamatsu; Toshihiro Miyamoto

doi:10.3324/haematol.2026.300852

Key Points

Characterize the clinical features, cerebrospinal fluid markers, and postmortem neuropathology of delayed parkinsonism-like neurotoxicity occurring after idecabtagene vicleucel therapy for multiple myeloma.
Assessed clinical course, neurological symptoms, and cerebrospinal fluid alterations in patient cases exhibiting delayed movement disorders following idecabtagene vicleucel administration.
Performed comprehensive postmortem histopathological and immunohistochemical examinations of brain tissue to determine patterns of neuroinflammation and cellular damage.
Identified delayed onset of parkinsonian movement abnormalities following idecabtagene vicleucel chimeric antigen receptor T-cell infusion.
Demonstrated cerebrospinal fluid inflammation and central nervous system pathology on autopsy, defining structural and cellular correlates of this delayed neurotoxic syndrome.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Clinicopathological investigation reports delayed parkinsonism-like neurotoxicity after idecabtagene vicleucel in multiple myeloma, highlighting rare postmortem central nervous system pathology.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Yoshino et al. (2026) studied this question.

synapsesocial.com/papers/6a92991a8e5d7d1fc0c10de3 https://doi.org/10.3324/haematol.2026.300852

View Full Paper

Ask AI

Bookmark

Share

Parkinsonism-like delayed neurotoxicity after idecabtagene vicleucel therapy for multiple myeloma: clinicopathological, cerebrospinal fluid, and autopsy analyses

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Parkinsonism-like delayed neurotoxicity after idecabtagene vicleucel therapy for multiple myeloma: clinicopathological, cerebrospinal fluid, and autopsy analyses

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Keep reading

Keep reading